UNION therapeutics A/S enters option agreement to acquire worldwide exclusive license for COVID-19 technologies developed by TFF Pharmaceuticals, Inc.
· Niclosamide identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than remdesivir · UNION has advanced niclosamide-based program for COVID-19 (UNI911) to clinical development, currently in Phase 1 study · TFF formulation technology can broaden the possible range of niclosamide formulations and treatments · Collaboration between UNION and TFF holds potential to make niclosamide treatments available to a broader range of patients globally Hellerup, Denmark, August 13 2020 – UNION therapeutics A/S (“UNION”) today announced the